When Is Mohs Surgery Chosen Over Standard Excision for Skin Cancer? How Surgeons Decide

The biopsy result arrives as a two-line message: basal cell carcinoma, right nasal ala. The next line says a referral has been made to a Mohs surgeon. Most people read that sentence twice. The dermatologist who took the biopsy removed a mole from the same person’s shoulder last year with a simple excision and a handful of stitches, so why does a pea-sized spot on the side of the nose need a different operation with a different name?

The answer is not that one method is better and the other is second-rate. The mohs surgery vs excision decision comes down to a handful of practical questions: where the tumor is, how its edges behave, whether it has been treated before, and how much healthy skin the surgeon can afford to sacrifice around it.

This explainer walks through how surgeons weigh those questions, what the two procedures actually involve, what the evidence does and does not show, and the questions worth bringing to your own appointment.

Mohs surgery vs excision: what each procedure actually removes

Both procedures aim at the same target: remove the visible tumor plus the invisible roots that spread outward under the skin, and confirm under a microscope that none was left behind. They differ in how that confirmation happens and in how much healthy tissue is taken to get there.

Standard surgical excision, sometimes called wide local excision, removes the tumor together with a rim of normal-looking skin around and beneath it. That rim is the margin, the safety buffer of healthy tissue a surgeon takes so that microscopic tumor cells hiding beyond the visible edge are caught too. The specimen goes to a pathology laboratory, where a small fraction of the edges is sliced, stained and examined. Results typically return in days, and the wound is usually closed on the day of surgery.

Mohs micrographic surgery, named for the surgeon who developed it, takes a much thinner rim of tissue and examines essentially the entire undersurface and outer edge of that specimen while the patient waits. If any margin shows cancer, the surgeon goes back and removes another thin layer only from the exact spot where cells were seen. The wound is closed once the last layer is clear. According to Mayo Clinic, this allows the surgeon to remove all the cancerous tissue while preserving as much healthy skin as possible.

The trade-off is straightforward. Excision is faster on the day, widely available and well suited to skin with room to spare. Mohs is longer, requires a specially trained team with an on-site laboratory, and earns its place where every millimeter of healthy skin matters or where the tumor’s edges cannot be trusted.

How Mohs surgery works, stage by stage

The procedure happens in cycles that surgeons call stages or layers. Understanding the rhythm makes the long waiting-room afternoon far less unnerving.

First, the surgeon injects local anesthetic, so the person is awake throughout. A thin, saucer-shaped layer of tissue is removed around the visible tumor, often with a shallow bevel so the deep surface and the edges can later lie flat on a slide. The surgeon nicks or inks the edges of the specimen and draws a matching map of the wound, so every point on the slide corresponds to a point on the patient.

The tissue is frozen, sliced horizontally, stained and read under the microscope. A frozen section is simply tissue chilled quickly so it can be cut and examined within about an hour rather than the days needed for conventional processing. In most Mohs practices the operating surgeon also reads the slides, which is part of what defines the technique; Johns Hopkins notes that the surgeon acts as both operator and pathologist.

If the slide is clean, the surgeon moves to repair. If cancer appears at one point on the map, only that region is re-excised. Mayo Clinic describes each round of laboratory processing as taking roughly an hour, so a two-stage case commonly fills a morning, and cases needing several stages can run most of a day.

The last step is reconstruction, which may be done by the Mohs surgeon or, for complex defects, by a colleague in plastic or facial surgery. The wound is only closed once the map shows every margin is clear, which is the entire point of the method.

Why location on the face changes the decision

Ask a Mohs surgeon which single factor drives most referrals and the answer is usually anatomy. Skin cancers on the central face behave differently and cost more to remove widely.

Dermatologists talk about the H zone: an H-shaped band across the face covering the nose, eyelids, inner corners of the eyes, lips, chin, ears and the skin in front of and behind the ears. Tumors here tend to grow along embryonic fusion planes, the seams where facial tissues joined during development, and can extend further under the surface than their visible size suggests. They also sit over structures that cannot be replaced: the tear ducts, the nasal cartilage, the edge of the lip.

Standard excision on a nose means taking a fixed margin of healthy skin whether or not the tumor actually extends that far, then closing a hole that may be twice the diameter of the visible spot. Mohs takes a narrow rim, checks it, and enlarges only where needed. On a shoulder blade, a few extra millimeters of skin are barely noticed. On an eyelid, they can be the difference between a lid that closes and one that does not.

The scalp, hands, feet, genitals and shins are also commonly treated with Mohs, less for cosmetic reasons than because these areas have little loose skin, heal slowly, or carry higher recurrence risk. Cleveland Clinic lists the face, ears, scalp, hands, feet and genitals among the sites where Mohs is most often chosen.

Location alone does not settle the question, but it is usually the first box a surgeon ticks when deciding between the two approaches.

Which tumor features push surgeons toward Mohs

Beyond location, the pathology report from the original biopsy carries several clues that tilt the decision. Each describes a tumor whose edges are harder to predict, which is exactly the situation Mohs was designed for.

• Aggressive growth pattern. Basal cell carcinoma, the most common skin cancer arising from cells at the base of the outer skin layer, comes in subtypes. Nodular tumors form a fairly compact ball; infiltrative, morpheaform and micronodular subtypes send thin strands outward like tree roots. Those strands can lie well beyond what the eye or a hand lens can see.
• Recurrence. A tumor that has come back after earlier surgery, freezing or creams is growing through scar tissue, and scar distorts the normal landmarks a surgeon relies on. Recurrent tumors are one of the most consistent reasons for Mohs referral, according to Mayo Clinic and Johns Hopkins.
• Size. Larger tumors carry more edge to check, and a wide fixed margin around a large tumor creates a very large defect.
• Ill-defined borders. If the dermatologist cannot draw a confident line around the lesion, a fixed margin is a guess.
• Perineural invasion. This means tumor cells tracking along a nerve, a feature seen mainly in squamous cell carcinoma, the second most common skin cancer, which arises from flatter cells higher in the epidermis. Nerve tracking can carry cells far from the main tumor.
• Immunosuppression. People who take medicines to prevent organ rejection or who have blood cancers can develop more numerous and more aggressive squamous cell carcinomas, and complete margin control is valued more highly.

Any one of these can justify Mohs on its own. Several together make the referral close to automatic in most practices.

Who is usually offered standard excision instead, and who is asked to wait

For all the attention Mohs receives, standard excision remains the workhorse of skin cancer surgery, and for good reason. Most basal cell carcinomas are small nodular tumors on the trunk, arms or legs with clear edges. Here a properly chosen margin removes the tumor with high reliability, the wound closes in a straight line, and the whole visit lasts well under an hour. The National Cancer Institute’s treatment summary lists surgical excision with margin evaluation as a standard option for basal and squamous cell carcinoma, alongside Mohs.

Standard excision is also the usual approach for invasive melanoma, a cancer of pigment cells, where guidelines specify wide margins based on tumor thickness and where lymph node assessment may run alongside the operation. Mohs has a role in some melanoma in situ cases on the face, but this remains a specialized decision.

Some people are asked to wait rather than choose. A biopsy that shows only a superficial basal cell carcinoma or a pre-cancerous actinic keratosis may be managed with a topical medicine, freezing, or scraping and cautery, and surgery is not needed at all. Someone taking a blood-thinning medicine is not usually asked to stop it for skin surgery, but the team may want to know about it. A person recovering from a recent heart event or a serious infection may be scheduled a few weeks later so the procedure can be done safely.

Waiting is rarely dangerous for basal cell carcinoma, which grows slowly over months to years. Squamous cell carcinoma can move faster, so the team may prioritize it. In either case the timing decision belongs to the treating clinician, who knows the specific tumor and the specific patient.

Mohs surgery vs excision at a glance

The table below summarizes how the two approaches differ on the points people most often ask about. It describes typical practice rather than a rule; individual teams vary.

Feature	Mohs micrographic surgery	Standard surgical excision
Margin taken	Thin rim, enlarged only where cancer is found	Fixed rim of healthy skin chosen in advance
Margin examined	Essentially the entire edge and undersurface	A sample of representative slices
Who reads the slides	Usually the operating surgeon, on site	A pathologist in a laboratory, later
Results timing	Same day, before the wound is closed	Days later, after the wound is closed
Visit length	Several hours; occasionally most of a day	Commonly under an hour
Typical sites	Face, ears, scalp, hands, feet, genitals	Trunk, arms, legs
Typical tumors	Recurrent, large, ill-defined or aggressive-subtype BCC and SCC	Small, well-defined primary BCC and SCC; invasive melanoma
Anesthesia	Local	Local for most cases
If margins are positive	Addressed on the spot with another layer	Second procedure scheduled

Two rows deserve emphasis. The margin examined row explains why Mohs is trusted for tricky edges: conventional processing looks at a small percentage of the perimeter, so a thin root of tumor can slip between the slices. The results timing row explains the practical appeal: with excision, a phone call days later may mean a second operation on a wound that has already been closed, whereas Mohs settles the question before the first stitch goes in.

Neither column is universally superior. The aim is to match the method to the tumor, and the last row in either column is a manageable event rather than a failure.

When is Mohs surgery not recommended?

People searching this question are often trying to make sense of a referral that did not come, or a Mohs surgeon who suggested a simpler operation. Both are common and usually reflect good judgment rather than rationing.

Mohs is generally not recommended when a simpler method achieves the same result. A small nodular basal cell carcinoma on the upper back does not need hours of margin mapping; a standard excision will clear it with skin to spare. Professional societies in the United States have published appropriate use criteria that steer Mohs toward higher-risk sites and tumor types, and steer it away from low-risk tumors on the trunk and limbs where the extra time and laboratory resources add little.

Mohs is also not the first choice when a tumor has clearly grown beyond the skin into bone, deep muscle or nearby lymph nodes. Frozen-section mapping works beautifully for skin and superficial soft tissue, but deep invasion calls for a multidisciplinary team that may combine surgery with radiotherapy or systemic treatment. The technique is likewise not standard for invasive melanoma, where guideline-defined wide margins and lymph node staging take precedence.

Some situations relate to the person rather than the tumor. Sitting through several hours of stages is demanding for someone with severe dementia, an inability to lie still, or a condition that makes prolonged local anesthesia unwise. In such cases a surgeon may choose a wider excision under a single anesthetic, or consider radiotherapy.

A final reason is simple availability. Not every region has a Mohs surgeon within practical reach, and for a low-risk tumor a timely standard excision is a perfectly sound choice. The treating team weighs all of this, and a different recommendation is not a lesser one.

What the evidence actually shows about recurrence

The honest summary is that both operations work well for most skin cancers, and Mohs shows its advantage most clearly in the high-risk situations it was designed for.

Much of the enthusiasm around Mohs rests on decades of large case series reporting very low recurrence for primary basal cell carcinoma and somewhat higher, but still low, recurrence for tumors that had already come back once. Case series are useful but they describe what happened in expert hands rather than a fair head-to-head comparison.

The best direct comparison is a randomized trial from the Netherlands that assigned people with high-risk facial basal cell carcinoma to Mohs or standard excision and followed them for a decade. It found fewer recurrences after Mohs for both primary and recurrent tumors, with the clearest difference in the recurrent group; the absolute gap for primary tumors was modest. A Cochrane systematic review of interventions for basal cell carcinoma, indexed in PubMed, judged the evidence for Mohs over excision in high-risk facial tumors as favorable but limited by the small number of trials. The National Cancer Institute’s treatment summary reaches a similar position, listing both as standard options and reserving Mohs for tumors where margin control matters most.

Several points follow from this. For a low-risk trunk tumor, no trial shows a meaningful benefit of Mohs over careful excision. For recurrent or aggressive facial tumors, the evidence favors Mohs. And the trials measured recurrence and tissue saved, not survival, because death from basal cell carcinoma is rare with either approach.

Figures quoted in advertising should be read with this context. A recurrence percentage from one center’s series is not a promise about any individual tumor.

What the surgery day and the following weeks usually look like

The Mohs day starts early and involves a great deal of sitting. After the first layer is removed, a temporary dressing goes on and the person returns to the waiting area while the tissue is processed. Mayo Clinic advises bringing a book, snacks and a companion, and blocking out the whole day even though many cases finish sooner. Stages are painless once the anesthetic is in; the main complaints are boredom and a cold waiting room.

Standard excision, by contrast, is typically a single visit of under an hour, with the pathology result arriving by phone or letter within about a week.

For either procedure, the first 48 hours are about pressure and rest. A bulky dressing stays on, the head is kept elevated for facial wounds, and heavy lifting and bending are avoided to limit bleeding and swelling. Bruising around the eyes after work on the nose or forehead is common and can look alarming before it fades.

Stitches on the face are often removed at around one week and on the body at two weeks or a little longer, depending on tension. Cleveland Clinic describes wound healing over several weeks, with scars continuing to soften and fade for up to a year. Skin grafts and flaps need extra care and more frequent visits in the early weeks.

The typical mohs surgery recovery time for a simple facial closure is a week or two of visible healing and a few weeks of avoiding strenuous exercise, sun and swimming. Larger repairs take longer. Your surgeon’s written instructions override any general timeline, including this one.

Repairing the wound: why the hole matters as much as the tumor

People fixate on the tumor, understandably, but surgeons spend a good part of their planning on what happens after it is gone. On the face, the repair often determines how the operation is remembered.

Once margins are clear, there are four broad options. The wound can be left to heal on its own, called second intention healing, which works well in concave areas such as the inner corner of the eye or the bowl of the ear and avoids extra incisions. It can be closed side to side in a line, ideally hidden in a natural crease. A flap can be created by loosening adjacent skin and sliding or rotating it into the gap, keeping its own blood supply. Or a graft, a patch of skin borrowed from elsewhere such as behind the ear, can be placed over the defect.

Mohs tends to produce the smallest possible defect, which widens the choice of repair and often allows a simpler closure than a fixed-margin excision at the same site would have created. This tissue-sparing effect is the practical reason cosmetic and functional outcomes are frequently cited as an advantage of Mohs on the face, as Johns Hopkins and Mayo Clinic both note.

Repairs carry their own risks: bleeding, infection, partial loss of a flap or graft, and scars that heal thicker than expected. Some people need a small revision months later. None of this is a sign that something went wrong; it is part of the normal spectrum of healing.

Ask your surgeon which repair they are considering and why. The answer says a great deal about how they have weighed the cancer against the cosmetic result.

Is there a new alternative to Mohs surgery?

Search results promise novel replacements, and it is fair to be curious. The current picture is that several alternatives to mohs surgery exist, most are not new, and none has displaced surgery for tumors where clear margins matter.

For superficial basal cell carcinoma and some thin squamous lesions, non-surgical options are well established: topical medicines that provoke an immune response or interfere with cell division, cryotherapy (freezing), curettage and electrodesiccation (scraping and cautery), and photodynamic therapy, which uses a light-activated cream. The NHS and the National Cancer Institute list these as standard choices for suitable low-risk tumors. They do not provide margin confirmation, so they are not offered for aggressive or recurrent tumors.

Radiotherapy is a longstanding alternative for people who cannot undergo surgery, or for tumors where surgery would be disfiguring. It requires many visits over weeks and carries late skin changes, so it is used selectively.

For advanced basal cell carcinoma that has spread or cannot be operated on, targeted medicines that block the hedgehog signaling pathway, a growth signal that is switched on in most basal cell carcinomas, are available; for advanced squamous cell carcinoma, immunotherapy that releases the brakes on the immune system is an option. These are decisions for an oncology team and are not substitutes for surgery in ordinary cases.

Imaging techniques such as reflectance confocal microscopy and optical coherence tomography are being studied as ways to map tumor edges before or during surgery without cutting. They are promising research tools, not proven replacements. If someone offers a treatment described as a new alternative to Mohs, ask what evidence supports it and whether guidelines include it.

Can skin cancer spread after Mohs surgery?

Two different worries hide inside this question, and they deserve separate answers.

The first is whether cutting into a tumor makes it spread. There is no good evidence that surgery seeds basal or squamous cell carcinoma into surrounding skin or the bloodstream. Basal cell carcinoma almost never spreads to distant sites regardless of treatment; the National Cancer Institute describes metastasis as extremely rare. Squamous cell carcinoma can spread to lymph nodes, particularly when it is large, deep, poorly differentiated, tracking along nerves, or occurring in someone with a suppressed immune system, and these risk factors are present before any surgery. Mohs, if anything, lowers the chance of leaving cells behind that could later grow.

The second worry is recurrence. A tumor can come back at the same site if microscopic cells escaped detection, which is uncommon after clear Mohs margins but not impossible. More often, what looks like recurrence is a new, separate skin cancer nearby, because the same sun-damaged skin that produced the first tumor is prone to producing others. Mayo Clinic notes that having one skin cancer raises the chance of developing another, which is why follow-up skin checks continue for years.

What this means in practice: after any skin cancer surgery, the team usually schedules regular full-skin examinations, often every six to twelve months at first, and asks you to report any new or changing spot, especially near the scar. For higher-risk squamous cell carcinoma, they may also examine the nearby lymph nodes at each visit.

Spread after Mohs is not something the operation causes. Vigilance afterward is about catching the next tumor early, not about a failure of the first treatment.

What people often get wrong about Mohs and excision

A handful of misunderstandings surface at nearly every pre-operative consultation. Correcting them tends to lower anxiety more than any reassurance about statistics.

Mohs is for serious cancers, so a Mohs referral means mine is dangerous. The referral usually reflects location or tumor pattern, not lethality. Most Mohs cases are basal cell carcinomas, which almost never threaten life.

Standard excision is the cheaper, inferior version. For a well-defined tumor on the trunk, excision is the right operation, not a compromise. Choosing Mohs there would add hours without adding safety.

Mohs means a tiny scar. Mohs minimizes the amount of tissue removed, but the tumor decides how large the defect is. A tumor with long roots produces a larger wound regardless of technique, and repair scars can be longer than the original spot.

The number of stages shows the surgeon missed something. Extra stages mean the tumor extended beyond what was visible, which is precisely what the method exists to detect. Two or three stages are routine.

Once the margins are clear, I am done with skin cancer. Sun damage is cumulative and widespread. Follow-up checks are for the next tumor as much as the last one.

Sunscreen after surgery is optional. New scars darken in sunlight and sun-damaged skin keeps producing tumors. Daily broad-spectrum sun protection is one of the few things within a patient’s control, as the CDC and Mayo Clinic advise.

I will be put to sleep. Nearly all Mohs and most excisions use local anesthesia. Being awake is part of what makes a day-long procedure practical.

Questions to ask your care team

A good consultation leaves room for questions. These are the ones surgeons say they are glad to be asked, because the answers shape both expectations and outcomes.

• Which features of my tumor or its location made you recommend Mohs, or made you recommend standard excision instead?
• What subtype did the biopsy show, and does that change the plan?
• If the margins come back positive after an excision, what happens next and how soon?
• How many stages do you expect, and how long should I plan to be there?
• Who will read the slides, and will the results be available before the wound is closed?
• What kind of repair are you considering, and could a different specialist be involved?
• Should I keep taking my usual medicines, including blood thinners or aspirin, on the day of surgery?
• What will the wound look like in the first week, and what is normal versus worrying?
• When can I return to work, exercise, driving and swimming?
• How often will I need skin checks afterward, and who will do them?
• Is there anything about my health, such as immune-suppressing treatment, that changes my risk of further skin cancers?

Write the answers down or bring someone to listen. People remember a fraction of what is said in a consultation, and the details about medicines and wound care are the ones most often forgotten.

Whatever the answers, the choice between the two operations, and the timing, belongs to you and the treating team together. A recommendation you do not understand is a reason to ask again, not a reason to worry.

When to call your doctor

Most recoveries from Mohs surgery and standard excision are uneventful, but the team wants to hear from you promptly if certain things happen. Keep the after-hours number they give you somewhere visible.

Call the same day, or seek urgent care if you cannot reach them, for bleeding that soaks through the dressing and does not stop after 15–20 minutes of firm, continuous pressure; a wound that suddenly swells, tightens and turns dark purple, which can signal blood collecting under the skin; fever, spreading redness, warmth, increasing pain or pus in the days after surgery, which are signs of infection; or a flap or graft that turns pale, gray or black.

Call within a day or two for stitches that have come loose before their removal date, a wound edge that has opened, numbness or weakness in the face that was not discussed beforehand, or pain that is climbing rather than easing after the first 48 hours.

Seek emergency care for chest pain, difficulty breathing, fainting, or an allergic reaction with hives, facial swelling or throat tightness, however unlikely these are after skin surgery.

In the months and years afterward, book an earlier appointment than scheduled for any new spot near the scar, a sore that does not heal within a few weeks, a scar that becomes lumpy or bleeds, or a new lump in the neck, armpit or groin on the same side as a treated squamous cell carcinoma. These are usually harmless, but they are exactly the changes the follow-up program exists to check, and the treating team would rather see you early than late.

Frequently asked questions

When is Mohs surgery not recommended?

Mohs is generally not recommended for small, well-defined basal or squamous cell carcinomas on the trunk or limbs, where standard excision clears the tumor with skin to spare, or for invasive melanoma, which is treated with guideline-defined wide margins. It is also not the first choice when a tumor has invaded bone or deep tissue, or when a person cannot tolerate several hours of staged surgery under local anesthesia.

What is the new alternative to Mohs surgery?

There is no proven new replacement for Mohs. Established alternatives include standard excision, curettage and cautery, cryotherapy, topical medicines, photodynamic therapy and radiotherapy, each suited to particular low-risk or inoperable situations. Imaging methods that map tumor edges without cutting are under study but remain research tools. For tumors where clear margins matter, surgery with margin control remains the standard the treating team will usually recommend.

What do people wish they knew before Mohs surgery?

The most common surprises are how long the day is, how much of it is spent waiting rather than in surgery, and how large the final wound and repair can be compared with the visible spot. People also underestimate the bruising after facial work and the number of weeks scars take to settle. Bringing food, a companion and realistic expectations about the repair makes the day considerably easier.

Can skin cancer spread after Mohs surgery?

Surgery does not cause basal or squamous cell carcinoma to spread. Basal cell carcinoma almost never reaches distant sites; squamous cell carcinoma can spread to lymph nodes when it is large, deep or in someone with a weakened immune system, and those risks exist before surgery. Recurrence at the site is uncommon after clear margins, and new spots nearby are usually separate tumors arising in sun-damaged skin.

What is the typical mohs surgery recovery time?

For a straightforward facial closure, visible healing takes roughly one to two weeks, with stitches often removed at around a week on the face and two weeks on the body. Strenuous exercise, swimming and sun exposure are usually limited for a few weeks. Scars continue to soften for up to a year. Flaps and grafts take longer and need closer follow-up, so your surgeon’s specific timeline should guide you.

Is Mohs surgery for basal cell carcinoma always necessary on the face?

Not always. Many facial basal cell carcinomas are referred for Mohs because tissue is precious there and tumors can extend along fusion planes, but a small nodular tumor on the cheek or forehead with clear edges may be treated with standard excision. The decision depends on subtype, size, border clarity and whether the tumor has been treated before, and it rests with the treating team.

Is Mohs surgery painful?

The procedure itself is done under local anesthetic and is not painful once the area is numb; the injection stings briefly. Between stages the wound is dressed and usually feels little. Afterward, most people describe soreness controlled with the measures the team recommends, more noticeable after larger repairs or on the scalp and ear. Pain that increases after the first two days should be reported.

Why does Mohs surgery take so long?

Each layer of tissue must be frozen, sliced, stained and read under the microscope before the surgeon knows whether to remove more, and that laboratory step takes about an hour per stage. A one-stage case can finish in a morning; a tumor with deeper roots needing three or four stages, plus a complex repair, can fill most of a day. The waiting is the price of same-day margin certainty.

What happens if margins are positive after a standard excision?

A positive margin means cancer cells were found at the edge of the removed tissue, so some tumor may remain. The team will usually recommend a second procedure, either a further excision or Mohs, sometimes after a short interval to let the wound settle. Occasionally, for low-risk tumors, close observation or radiotherapy is discussed. The right next step depends on the tumor type and site.

How often will I need skin checks after skin cancer surgery?

Most teams schedule full-skin examinations every six to twelve months at first, because having one skin cancer raises the chance of developing another in sun-damaged skin. People with squamous cell carcinoma, immunosuppression or multiple previous tumors may be seen more often, sometimes with lymph node examination. The schedule is set by your treating clinician and adjusted over time based on what is found.

References

• NHS: Non-melanoma skin cancer, Treatment
• CDC: Skin Cancer Prevention

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.